Company profile
COGENT BIOSCIENCES, INC.
NASDAQ:COGTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BEZUCLASTINIB | phase3 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04996875 | phase2 | recruiting | 2021-11-09 | 2025-09-19 | Cogent Biosciences, Inc. | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis |
| NCT05208047 | phase3 | recruiting | 2022-04-14 | 2025-09-30 | Cogent Biosciences, Inc. | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors |
| NCT05186753 | phase2 | active_not_recruiting | 2022-06-27 | 2025-05-22 | Cogent Biosciences, Inc. | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis |
| NCT07383506 | phase1 | recruiting | 2026-07-23 | 2029-07-01 | Cogent Biosciences, Inc. | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors |
| NCT07361562 | phase1 | recruiting | 2025-12-30 | 2028-05-01 | Cogent Biosciences, Inc. | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors |
FDA applications (0)
No records yet.